Zila, Inc. (ZILA)

[Play_Chips]

About Oral Cancer and ViziLite Plus

One American dies every hour of oral cancer and while tobacco and alcohol use are known risk factors, one quarter of all oral cancer cases occur in men and women with no risk behaviors. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.

ViziLite Plus is an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented pharmaceutical-grade vital tissue dye (TBlue). The ViziLite Plus exam takes only minutes and is totally painless and non-invasive. Zila began marketing the product through its direct sales force in the U.S. in February 2007, in Canada in November 2007, and will launch ViziLite Plus in Europe in May 2008.